FOXO4-DRI
Senolytic peptide developed by Peter de Keizer at Utrecht University (2017). FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent cells — so-called 'zombie cells' that accumulate with aging and secrete harmful inflammatory factors. In aged mice studies, the peptide restored physical vigor, fur density, and kidney function, making it one of the most discussed anti-aging compounds in the scientific community.
Last updated:: 13/04/2026
Research Status
ANVISA (Brazil)
Not regulated
FDA (USA)
Not regulated
EMA (Europe)
Not regulated
Mechanism of Action
FOXO4-DRI works by disrupting the interaction between the FOXO4 and p53 proteins within senescent cells. Normally, FOXO4 binds to p53 in the nucleus of senescent cells, preventing p53 from activating the apoptosis (programmed cell death) pathway. The FOXO4-DRI peptide competes with endogenous FOXO4 for this binding, displacing p53 to the cytoplasm. Once free in the cytoplasm, p53 activates the mitochondrial apoptosis cascade, leading to selective death of the senescent cell. Healthy cells are unaffected because they do not depend on the FOXO4-p53 interaction for survival. The D-retro-inverso structure (D-amino acids in reversed sequence) confers resistance to protease degradation, increasing the peptide's in vivo half-life.
Study Protocols
Dosages and regimens used in published clinical studies. This does not constitute a medical prescription.
Clearance de células senescentes (senolítico)
Intraperitoneal (IP) — dados apenas em animaisApenas dados pré-clínicos. Sem estudos humanos.
Peptídeo D-retro-inverso que bloqueia interação FOXO4-p53, induzindo apoptose seletiva de células senescentes. Em camundongos envelhecidos: restauração de pelagem, fitness renal e performance física. NÃO existem protocolos humanos validados — qualquer dose humana circulando online é extrapolação sem base clínica.
Benefits
Elimination of senescent cells
ProvenIn aged and genetically modified mice, FOXO4-DRI significantly reduced the senescent cell burden in multiple tissues, including liver, kidney, and intestine.
View studyAnti-aging potential
Under researchMice treated with FOXO4-DRI showed improvements in physical activity, overall appearance, and aging markers. Senolysis is considered one of the most promising strategies against biological aging.
Fur regeneration in aged mice
ProvenNaturally aged mice treated with FOXO4-DRI showed significant fur regeneration, indicating hair follicle rejuvenation after the elimination of senescent cells.
View studyImproved kidney function
Under researchTreated mice showed improved kidney function, measured by reduced plasma urea levels, suggesting that eliminating senescent cells in the kidneys may partially restore organ function.
Risks and Side Effects
Extremely high cost
High(Always)FOXO4-DRI synthesis is complex and expensive due to its D-retro-inverso structure (48 D-amino acids). Estimated cost per dose is thousands of dollars, making it inaccessible to most people.
Unknown long-term effects
Moderate(Unknown)No long-term studies exist, not even in animals. The effects of chronic senescent cell elimination over years are completely unknown.
Risk of eliminating beneficial senescent cells
Moderate(Theoretical)Not all senescent cells are harmful. Some play important roles in wound healing, tumor suppression, and embryonic development. Indiscriminate elimination may have unexpected consequences.
Complete absence of human data
High(N/A)No human clinical trial exists. All evidence comes from mice. Translating results from murine models to humans frequently fails, especially in anti-aging interventions.
Internet vs. Science
What people say online compared to the actual scientific evidence.
FOXO4-DRI reverses aging
Partially trueWhat they claim
The peptide rejuvenates the entire body, reversing years of aging in just a few weeks.
Actual evidence
In mice, there were improvements in specific aging markers (fur, kidney function, physical activity). This is not 'aging reversal' — it is the removal of one factor contributing to functional decline. Aging is multifactorial and no single compound 'reverses' it.
Already available for human use
FalseWhat they claim
Longevity clinics and peptide suppliers offer FOXO4-DRI for human administration.
Actual evidence
There is NO completed or ongoing human clinical trial. Any use in humans is completely experimental, without established safety data, pharmacokinetics, or dosing for our species.
FOXO4-DRI cures cancer
FalseWhat they claim
Since it eliminates old and damaged cells, the peptide can cure or prevent cancer.
Actual evidence
The relationship between cellular senescence and cancer is complex. Senescent cells can both suppress and promote tumors (via SASP — senescence-associated secretory phenotype). Eliminating senescent cells may reduce the pro-tumoral microenvironment but also remove a barrier against the proliferation of pre-malignant cells. There is no evidence that FOXO4-DRI prevents or treats cancer.
| Claim | O que dizem | Evidência real | Verdict |
|---|---|---|---|
| FOXO4-DRI reverses aging | The peptide rejuvenates the entire body, reversing years of aging in just a few weeks. | In mice, there were improvements in specific aging markers (fur, kidney function, physical activity). This is not 'aging reversal' — it is the removal of one factor contributing to functional decline. Aging is multifactorial and no single compound 'reverses' it. | Partially true |
| Already available for human use | Longevity clinics and peptide suppliers offer FOXO4-DRI for human administration. | There is NO completed or ongoing human clinical trial. Any use in humans is completely experimental, without established safety data, pharmacokinetics, or dosing for our species. | False |
| FOXO4-DRI cures cancer | Since it eliminates old and damaged cells, the peptide can cure or prevent cancer. | The relationship between cellular senescence and cancer is complex. Senescent cells can both suppress and promote tumors (via SASP — senescence-associated secretory phenotype). Eliminating senescent cells may reduce the pro-tumoral microenvironment but also remove a barrier against the proliferation of pre-malignant cells. There is no evidence that FOXO4-DRI prevents or treats cancer. | False |
Studies and References (2)
McHugh D, Gil J. — Nature Reviews Molecular Cell Biology (2018)
Revisão abrangente sobre senescência celular e estratégias senolíticas, incluindo o FOXO4-DRI. Contextualiza o peptídeo dentro do campo mais amplo de intervenções anti-envelhecimento e discute os desafios de tradução clínica das abordagens senolíticas.
PubMedBaar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourber BRM, Stryber S, Rijksen Y, van Willigenburg H, Feijtel DA, et al. — Cell (2017)
Estudo original que descreveu o FOXO4-DRI. Demonstrou que o peptídeo induz apoptose seletiva em células senescentes in vitro e in vivo. Em camundongos envelhecidos naturalmente, restaurou a aptidão física, densidade de pelos e função renal. Em camundongos tratados com quimioterapia (doxorrubicina), neutralizou a senescência induzida.
PubMedFrequently Asked Questions
What are senescent cells and why eliminate them?
Senescent cells are cells that have stopped dividing but do not die. They accumulate with age and secrete inflammatory substances (called SASP) that damage neighboring tissues, contributing to cardiovascular disease, neurodegeneration, arthritis, and other age-associated conditions. Eliminating these 'zombie cells' is one of the most promising strategies in anti-aging medicine.
Can I use FOXO4-DRI in humans today?
There is no human safety data. No clinical trials have been completed or are underway. Dosing, pharmacokinetics, and side effects in humans are completely unknown. Any use is experimental and risky. Additionally, synthesis costs are prohibitive — thousands of dollars per dose.
What is the difference between FOXO4-DRI and other senolytics like dasatinib + quercetin?
Dasatinib + quercetin (D+Q) are small molecules already approved for other uses (dasatinib is a chemotherapy drug) and are much more accessible. FOXO4-DRI is a peptide specifically designed for senolysis with a more selective mechanism (blocks FOXO4-p53). In practice, D+Q has more human clinical data, while FOXO4-DRI remains restricted to animal studies.
Do the mouse results translate to humans?
Not always. Aging biology in mice differs significantly from humans. Mice live ~2 years, so changes in aging markers are easier to detect. Many promising anti-aging interventions in mice have failed when tested in humans. FOXO4-DRI still needs rigorous clinical trials to determine whether the benefits observed in rodents apply to people.
Important notice
This content is strictly informational and educational, based on published scientific research. It does not constitute medical advice, prescription, or encouragement to use any substance. Always consult a qualified physician before starting any treatment.
Not Yet Available
This compound is still experimental and has not been approved for use. Sign up to be notified when it becomes available.